Prøve GULL - Gratis
‘Click M' For Mental Health
BioSpectrum Asia
|February 2022
Mental health and wellbeing has become a major cause for concern, especially due to the pandemic-induced psychological traumas, stemming from spending long hours in the confines of one’s home, minimal to zero social interaction, inability to meet and greet friends and family, as before and financial insecurity. Little wonder that the mental health space turned out to be ‘the hot’ sector in 2021, with funding more than doubling globally, climbing from $2.3 billion to $5.5 billion. As app-based mental health solutions are becoming a rage in APAC, we take a quick look at a few promising players.
Even then, mental health remained an issue largely unaddressed, almost neglected, until now. In recent times, there has been a flurry of activities and funding in the sector which aim to bridge this gap. COVID-19, focus on preventive health, limited number of psychiatrists and the narrow access to clinical treatment in the region have all fuelled the adoption of apps for such disorders.
Based on the Asia-Pacific Front Line of Healthcare Report 2019, 34 per cent of physicians believe mental health service can be delivered digitally and 20 per cent are confident it can be powered by machine learning in the next 5 years.
Market is also set to reflect that. According to a report by Market Data Forecast, the size of the mental health software market was valued at $0.31 billion in 2021 and is estimated to be growing at a CAGR of 14.86 per cent reaching $0.62 billion by 2026.
Denne historien er fra February 2022-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits
US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation
US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio
Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema
A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing
Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO
Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
IIT-D and AIIMS develop swallowable microdevice for microbiome study
Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Ambitious research to develop multivalent vaccines against multiple deadly filoviruses
Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.
1 min
BioSpectrum Asia Feb 2026
Translate
Change font size
